Ixazomib citrate
As of the edition of 20 October 2026, Ixazomib citrate is a small molecule: marketed, first approved in 2015 (US); acts on PSMB5; US protection ends in 2029.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Small molecule
- Brand name
- Ninlaro
- First approved
- 20 November 2015 (US)
- Approvals on record
- 9 in 3 regions
- Holder of the most recent approval
- Takeda
- Registered trials
- 50, 9 stopped early
- Disease areas
- Cancer; Immune system; Blood and lymph; Heart and blood vessels; Infections; Nervous system
US protection
US protection ends in 2029.
The last listed US drug-substance patent ends in 2029. The application that gives this date is held by Takeda.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product15 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 15 listings behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PSMB5 | Proteasome subunit beta type-5 | P28074 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 13 | 8 | 2 | 3 |
| Phase 2 | 33 | 22 | 4 | 6 |
| Phase 3 | 4 | 3 | 0 | 0 |
| All trials | 50 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Takeda | Originator, Applicant and Lead sponsor of trials | 2009 to now |